Please assess the completion status of the following clinical trial:

Trial Title: Olivamine-containing Products in the Management of Patients With Nonhealing Lower Extremity Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is 18 years old or older.~* Patient has a diagnosis of arterial, diabetic foot, venous insufficiency, or pressure ulcer or surgical and traumatic wound.~* Patient's target study ulcer/wound is a lower extremity full thickness ulcer/wound not involving tendon, capsule, or bone.~* Patient's target study ulcer/wound and is ≥1.0 cm2 and ≤ 10.0 cm2 in size at the day of initial consult.~* Study ulcer/wound has been present for greater than 6 weeks prior to initial consult.~* Patients with Charcot foot deformities can be entered so long as the Charcot disease is not active, and the ulcer can be offloaded by an orthotic device.~* The patient has adequate circulation to the lower extremity as evidenced by an ABI (measured by Doppler) of ≥ 0.7. If the patient has non-compressible leg arteries, as documented by an ABI \>1.3, then the patient must have a Toe-Brachial Index be \> 0.6, or a toe pressure \>50 mm Hg.~* Patient must have adequate in-home support to comply with all protocol-mandated visits and procedures, offloading or pressure redistribution as required, and proper application of study products and wound care regimen.~* Patient or his/her legal representative has read and signed the Institutional Review Board-approved Informed Consent form before Screening.~Exclusion Criteria:~* An ulcer/wound that is ≥10.0 cm2 and ≤ 1.0 cm2 in size at the day of initial consult is not eligible for this study.~* Patient has clinical evidence of gangrene or infection on any part of the affected foot.~* The patient is judged by the investigator or study staff to be unable or unlikely to comply with daily wound care instructions, or study visits.~* Patient has clinical evidence of active sepsis or invasive infection (e.g., cellulitis, osteomyelitis).~* Patient has muscle, tendon, or bone exposure in any ulcer bed.~* Patient has known sensitivity or allergy to any component of the study product - Olivamine10.~* Patient has one or more medical condition(s), including renal, hepatic, hematologic, neurologic, or immune disease that in the opinion of the - Investigator would make the patient an inappropriate candidate for this wound healing study.~* Patient has a malignant disease (other than squamous or basal cell carcinoma of the skin) not in remission for five years or more.~* Patient has known alcohol or drug abuse.~* Patient has a hematocrit greater than 60% or less than 27%.~* Patient's diabetes is under poor control as manifested by HbA1c of \>10.0%.~* Patient has clinically significant renal insufficiency or creatinine greater than 2.0 mg/dL.~* Patient has chronic liver disease or clinically significant liver enzyme abnormality as evidenced by elevated AST, ALT, or bilirubin greater than 1.5 times upper limit of normal (ULN).~* Patient is receiving oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, or is anticipated to require such agents during the course of the study.~* Patient is using tobacco, or is exposed to a current smoker in their household. Patients may participate in the study if they have not used tobacco for 3 months and have not had a smoker in their household for 3 months.~* Patient is using any form of nicotine including nicotine patches, gums, or sprays.~* Patient has Acquired Immunodeficiency Syndrome (AIDS) or is known to be infected with Human Immunodeficiency Virus (HIV).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic Wound Group (Type: None): Treatment with Olivamine containing wound care products

Based on this trial design, predict the completion outcome and termination type (if applicable).